Business Wire

ANT-INTERNATIONAL

18.6.2024 09:36:33 CEST | Business Wire | Press release

Share
Ant International Unveils Global SME Digital Lending Service Through Embedded Finance to Accelerate Financial Inclusion

Ant International, a leading global digital payment and financial technology provider, today unveiled bettr, a global digital lending service to provide micro lending to micro, small and medium enterprises (MSMEs) in strategic markets through embedded finance partnerships.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240618515438/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Wallapa Traisorat, CEO and President of Asset World Corporation (second from left) and Yang Peng, CEO of Ant International (second from right) at the MOU signing ceremony between bettr and AWC (Photo: Business Wire)

Yang Peng, CEO of Ant International said, “I’m thrilled to introduce bettr to SMEs and industry partners across emerging markets. This is a major milestone in our journey to empower SMEs worldwide with innovative fintech solutions through open collaboration with regional partners. bettr’s mission is to make financing simpler and more accessible for micro and small businesses as they become the new engine for regional and cross-border trade and commerce. We look forward to expanding partnerships with leaders across industries to achieve our shared vision for an inclusive, sustainable future commerce ecosystem.”

The IFC estimates that 65 million firms, or 40%1 of formal MSMEs in developing countries, have an unmet financing need of $5.2 trillion every year. Recognising the unmet need for inclusive and accessible financial services globally, bettr aims to enable an open, collaborative ecosystem to enhance the accessibility and ease of credit support by leveraging AI, privacy-preserving computing and other digital innovations to close the financing divide and unlock growth opportunities for MSMEs.

Marking the launch, bettr announced its inaugural embedded finance collaboration with Asset World Corporation (“AWC”), Thailand’s leading integrated lifestyle real estate group and a member of the TCC Group. Wallapa Traisorat, CEO and President of AWC said, “AWC is very excited to partner with Ant International for the launch of bettr. This collaboration will allow both parties to fully leverage their strengths where bettr will intuitively avail digital lending to AWC’s ecosystem of micro and small businesses via our various platforms and engagement channels. The first phase of this partnership will launch AWC’s flagship project “Phenix,” the world’s food wholesale hub, featuring the largest food lounge in Pratunam, set to open on 26th June 2024. The partnership is expected to benefit sellers, buyers, and AWC suppliers, conducting business on Phenix both online and offline, and will eventually benefit merchants across AWC’s Hospitality, Retail and Wholesale and Commercial businesses.”

“With a booming SME economy, Thailand has been a strategic market for Ant International from day one, where we learned from deep-rooted partnerships and serve thousands of local businesses through digital payments, connecting them with global travelers and export markets. With bettr, we are now able to expand the financial services offerings by providing accessible financing, empowering small businesses to grow and thrive," added Yang Peng.

About bettr

bettr is the digital lending business under Ant International, focused on providing inclusive financial services to micro, small and medium enterprises (MSMEs) in strategic markets through partners via embedded finance. By leveraging its innovation-led tech like AI and privacy-preserving computing to enable secure financing solutions, bettr enhances the accessibility and ease of financing, unlocking growth opportunities for MSMEs. For more information on bettr, please visit https://www.bettrfinancing.com/

About Ant International

Headquartered in Singapore, Ant International powers the future of global commerce with digital innovation for everyone and every business to thrive. In close collaboration with partners, we support merchants of all sizes worldwide to realize their growth aspirations through a comprehensive range of tech-driven digital payment and financial services solutions.

1 Source: https://www.worldbank.org/en/topic/smefinance

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240618515438/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye